NCT06824818NARecruiting

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

University of Chicago

Start Date

6/1/2026

Completion Date

6/1/2027

Summary

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Eligibility Criteria

Age Range: 70 years to No maximum

Inclusion Criteria: * Prostate cancer with \>3 years of LHRH agonist therapy. * Age ≥70 years. * ECOG performance status ≤2 * Baseline testosterone of \< 20 ng/ml * No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable). * Ability to understand and sign informed consent. Exclusion Criteria: * none

Interventions

BEHAVIORAL

LHRH Agonist Therapy Discontinuation

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

ElderlyProstate Cancer

Locations

The University of Illinois at Chicago (UIC)

Chicago, Illinois 60607

United States

UChicago Medicine Comprehensive Cancer Center

Chicago, Illinois 60637

United States